HLB announced on the 29th that it has completed the resubmission of its New Drug Application (NDA) and Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the combination therapy of its lead candidate, Rivoceranib, and the PD-1 inhibitor Camrelizumab, intended as a first-line treatment for unresectable hepatocellular carcinoma (liver cancer).
Strategic Regulatory Pivot
Following a Complete Response Letter (CRL) issued by the FDA earlier this year, which cited issues related to the Camrelizumab manufacturing facility and the need for additional clinical data, HLB and its partner, Hengrui Pharma, have spent recent months addressing these deficiencies. The company confirmed that all requested supplementary documentation has been compiled and submitted for regulatory review.
Market Outlook and Impact
The resubmission is being closely watched by the market, as the successful commercialization of this combination therapy is considered a cornerstone of HLB’s future growth trajectory. Analysts noted that the company’s ability to navigate the FDA’s stringent approval process will be a critical determinant for its valuation on the KOSDAQ. Market participants are now shifting their focus toward the FDA's anticipated Prescription Drug User Fee Act (PDUFA) action date, which will dictate the timeline for potential market entry.
Industry experts suggest that if approved, the therapy could pose a significant challenge to existing treatments in the global liver cancer market, given the clinical efficacy demonstrated in Phase 3 trials.
In related market activity, major domestic players such as Samsung Electronics, SK hynix, and Hyundai Motor continue to anchor the KOSPI, while the performance of other prominent firms like Alteogen and Hyosung Heavy Industries remains in focus amid broader market fluctuations.
Note: This report includes observations on the broader landscape of Korean equities and does not constitute investment advice.
